Guillain-Barré syndrome in a patient on adalimumab for the treatment of psoriasis

Abstract The use of TNF-α inhibitors for the treatment of moderate to severe psoriasis and psoriatic arthritis is increasingly more frequent. The authors report a case of Guillain-Barré syndrome as a late manifestation of the treatment with adalimumab. Although unusual, this is relevant for professi...

Full description

Bibliographic Details
Main Authors: Natallia Barreiros de Natividade, Paulo Antonio Oldani Felix, Claudio Lerer
Format: Article
Language:English
Published: Sociedade Brasileira de Dermatologia 2017-01-01
Series:Anais Brasileiros de Dermatologia
Subjects:
Online Access:http://www.scielo.br/pdf/abd/v92n5s1/0365-0596-abd-92-05-s1-0085.pdf
Description
Summary:Abstract The use of TNF-α inhibitors for the treatment of moderate to severe psoriasis and psoriatic arthritis is increasingly more frequent. The authors report a case of Guillain-Barré syndrome as a late manifestation of the treatment with adalimumab. Although unusual, this is relevant for professionals who prescribe biologic drugs. We also stress the importance of investigating the past and family medical history regarding demyelinating diseases before starting treatment.
ISSN:0365-0596